These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15530292)

  • 21. Calcium hydroxylapatite facial filler (Radiesse): indications, technique, and results.
    Jacovella PF
    Clin Plast Surg; 2006 Oct; 33(4):511-23. PubMed ID: 17085220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monophasic, cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients.
    Pavicic T; Ruzicka T; Korting HC; Gauglitz G
    J Drugs Dermatol; 2010 Jun; 9(6):690-5. PubMed ID: 20645533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restorative interventions for HIV facial lipoatrophy.
    Carey D; Liew S; Emery S
    AIDS Rev; 2008; 10(2):116-24. PubMed ID: 18615122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcium hydroxylapatite for facial rejuvenation.
    Berlin A; Cohen JL; Goldberg DJ
    Semin Cutan Med Surg; 2006 Sep; 25(3):132-7. PubMed ID: 17055392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimizing discomfort during the injection of Radiesse with the use of either local anesthetic or ice.
    Comite S; Greene A; Cieszynski SA; Zaroovabeli P; Marks K
    Dermatol Online J; 2007 Jul; 13(3):5. PubMed ID: 18328199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
    Parruti G; Toro GM
    BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiance.
    Flaharty P
    Facial Plast Surg; 2004 May; 20(2):165-9. PubMed ID: 15643585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-density hyaluronic acid for the treatment of HIV-related facial lipoatrophy.
    Pignatti M; Pedone A; Baccarani A; Guaraldi G; Orlando G; Lombardi M; De Santis G
    Aesthetic Plast Surg; 2012 Feb; 36(1):180-5. PubMed ID: 21717261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management options for facial lipoatrophy.
    Cofrancesco J; Brown T; Martins CR
    AIDS Read; 2004 Dec; 14(12):639-40, 645-50. PubMed ID: 15619779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trial of a novel filler material for soft tissue augmentation of the face containing synthetic calcium hydroxylapatite microspheres.
    Roy D; Sadick N; Mangat D
    Dermatol Surg; 2006 Sep; 32(9):1134-9. PubMed ID: 16970693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique.
    Burnouf M; Buffet M; Schwarzinger M; Roman P; Bui P; Prévot M; Deleuze J; Morini JP; Franck N; Gorin I; Dupin N
    Arch Dermatol; 2005 Oct; 141(10):1220-4. PubMed ID: 16230558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Injectable calcium hydroxylapatite microspheres (Radiesse).
    Ridenour B; Kontis TC
    Facial Plast Surg; 2009 May; 25(2):100-5. PubMed ID: 19415577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of one-step rehabilitation of human immunodeficiency virus-related facial lipoatrophy using an injectable calcium hydroxylapatite dermal filler.
    Rauso R; Curinga G; Rusciani A; Colella G; Amore R; Tartaro G
    Dermatol Surg; 2013 Dec; 39(12):1887-94. PubMed ID: 24299576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive.
    Bergersen BM; Sandvik L; Ellingsen I; Bruun JN
    HIV Med; 2005 Jul; 6(4):260-7. PubMed ID: 16011531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 52-month summary of results using calcium hydroxylapatite for facial soft tissue augmentation.
    Tzikas TL
    Dermatol Surg; 2008 Jun; 34 Suppl 1():S9-15. PubMed ID: 18547188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of facial lipoatrophy in HIV-infected patients.
    Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
    Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S
    J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Injectable calcium hydroxylapatite for correction of nasal bridge deformities.
    Siclovan HR; Jomah JA
    Aesthetic Plast Surg; 2009 Jul; 33(4):544-8. PubMed ID: 19067034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-slice computed tomography and anthropometric skinfold analysis for evaluation of facial lipoatrophy in HIV-infected patients.
    Padilla S; Gallego JA; Masiá M; Gutiérrez F
    Clin Infect Dis; 2004 Dec; 39(12):1848-51. PubMed ID: 15578410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.